Monoclonal antibody and biologic DMARD drug classes with their mechanism and one signature side effect per card, distinct from the innate and adaptive immune cell focus of the Immunology decks.
35 cards · basic cards · AI-written, checked twice. Edit anything.
- Infliximab: antibody class and target?
- Chimeric monoclonal antibody against TNF-alpha
- Signature adverse effect of infliximab?
- Reactivation of latent tuberculosis
- How does etanercept differ structurally from other anti-TNF drugs?
- It is a fusion protein of the TNF receptor and IgG Fc region, not a true monoclonal antibody
- Adalimumab: antibody class and target?
- Fully human monoclonal antibody against TNF-alpha
- Signature neurologic risk of anti-TNF therapy as a drug class?
- Increased risk of demyelinating disease resembling multiple sclerosis
- Rituximab mechanism of action?
- Monoclonal antibody against CD20 that depletes B lymphocytes
- Signature risk of rituximab therapy?
- Progressive multifocal leukoencephalopathy from JC virus reactivation
- Trastuzumab target?
- HER2/neu receptor
- Signature adverse effect of trastuzumab?
- Cardiotoxicity (reduced left ventricular ejection fraction)
- Bevacizumab mechanism of action?
- Monoclonal antibody against VEGF that inhibits angiogenesis
- Signature adverse effect of bevacizumab?
- Gastrointestinal perforation
- Cetuximab target?
- Epidermal growth factor receptor (EGFR)
- Signature adverse effect of cetuximab?
- Acneiform (papulopustular) rash
- Natalizumab mechanism of action?
- Monoclonal antibody against alpha-4 integrin that blocks leukocyte migration across the blood brain barrier
- Signature risk of natalizumab therapy?
- Progressive multifocal leukoencephalopathy from JC virus reactivation